Rubicon Technology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Rubicon Technology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.59M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $4.06M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $3.62M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $3.53M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $3.88M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $5.04M | Mar 22, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.44M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $1.26M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.01M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.08M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $16.0K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($5.51M) | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | ($4.89M) | Mar 16, 2017 |
| FY2016 | Sep 30, 2016 | ($11.65M) | Mar 16, 2017 |
| FY2016 | Jun 30, 2016 | ($4.05M) | Mar 16, 2017 |
| FY2016 | Mar 31, 2016 | ($5.42M) | Mar 16, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $935.0K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | ($730.0K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($1.06M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.15M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $963.0K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($17.85M) | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | ($22.54M) | Mar 16, 2017 |
| FY2016 | Sep 30, 2016 | ($24.80M) | Mar 16, 2017 |
| FY2016 | Jun 30, 2016 | ($8.21M) | Mar 16, 2017 |
| FY2016 | Mar 31, 2016 | ($7.33M) | Mar 16, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $585.0K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | ($464.0K) | Mar 30, 2023 |
| FY2020 | Dec 31, 2020 | $530.0K | Mar 23, 2021 |
| FY2020 | Dec 31, 2019 | ($1.25M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $635.0K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($17.92M) | Mar 22, 2019 |
| FY2016 | Dec 31, 2016 | ($21.64M) | Mar 16, 2017 |
| FY2016 | Sep 30, 2016 | ($24.77M) | Mar 16, 2017 |
| FY2016 | Jun 30, 2016 | ($8.15M) | Mar 16, 2017 |
| FY2016 | Mar 31, 2016 | ($8.16M) | Mar 16, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $662.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2021 | $662.0K | Mar 28, 2022 |
| FY2019 | Dec 31, 2018 | $122.0K | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $962.0K | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $2.55M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $2.21M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $1.86M | Mar 14, 2016 |
| FY2015 | Dec 31, 2013 | $2.26M | Mar 14, 2016 |
| FY2014 | Dec 31, 2012 | $2.27M | Mar 13, 2015 |
| FY2013 | Dec 31, 2011 | $1.81M | Mar 13, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $297.0K | Mar 23, 2021 |
| FY2020 | Dec 31, 2019 | ($1.23M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($1.07M) | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($2.03M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($15.29M) | Mar 20, 2018 |
| FY2013 | Dec 31, 2013 | $412.0K | Mar 13, 2014 |
| FY2013 | Dec 31, 2012 | ($2.74M) | Mar 13, 2014 |
| FY2013 | Dec 31, 2011 | $24.61M | Mar 13, 2014 |
| FY2012 | Dec 31, 2010 | $24.06M | Mar 14, 2013 |
| FY2011 | Dec 31, 2009 | ($3.29M) | Mar 15, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $2.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $64.0K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $2.28M | Mar 23, 2020 |
| FY2017 | Dec 31, 2016 | $704.0K | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $941.0K | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $6.84M | Mar 14, 2016 |
| FY2015 | Dec 31, 2013 | $8.72M | Mar 14, 2016 |
| FY2014 | Dec 31, 2012 | $10.98M | Mar 13, 2015 |
| FY2013 | Dec 31, 2011 | $48.23M | Mar 13, 2014 |
| FY2012 | Dec 31, 2010 | $49.43M | Mar 14, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.96M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $30.99M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $31.24M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $34.80M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $35.79M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $35.05M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $53.01M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $119.24M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $194.91M | Mar 14, 2016 |
| FY2014 | Dec 31, 2013 | $202.70M | Mar 13, 2015 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.76M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $1.60M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.31M | Mar 28, 2022 |
| FY2016 | Dec 31, 2016 | $2.56M | Mar 16, 2017 |
| FY2016 | Dec 31, 2015 | $7.26M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $6.35M | Mar 14, 2016 |
| FY2014 | Dec 31, 2013 | $6.90M | Mar 13, 2015 |
| FY2013 | Dec 31, 2012 | $22.71M | Mar 13, 2014 |
| FY2012 | Dec 31, 2011 | $31.72M | Mar 14, 2013 |
| FY2011 | Dec 31, 2010 | $14.65M | Mar 15, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.20M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $29.39M | Mar 30, 2023 |
| FY2022 | Dec 31, 2020 | $29.94M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $33.25M | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $34.60M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | $33.33M | Mar 23, 2020 |
| FY2018 | Dec 31, 2016 | $50.45M | Mar 22, 2019 |
| FY2017 | Dec 31, 2015 | $111.99M | Mar 20, 2018 |
| FY2016 | Dec 31, 2014 | $188.56M | Mar 16, 2017 |
| FY2015 | Dec 31, 2013 | $195.79M | Mar 14, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($331.20M) | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | ($332.13M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($331.40M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($330.34M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($329.19M) | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | ($330.16M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($312.31M) | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | ($249.43M) | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | ($171.60M) | Mar 14, 2016 |
| FY2014 | Dec 31, 2013 | ($127.60M) | Mar 13, 2015 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.59M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $11.26M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.13M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $8.71M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $11.24M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | $11.54M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $17.67M | Mar 20, 2018 |
| FY2017 | Dec 31, 2015 | $21.22M | Mar 20, 2018 |
| FY2016 | Dec 31, 2014 | $24.35M | Mar 16, 2017 |
| FY2015 | Dec 31, 2013 | $21.07M | Mar 14, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 0 | Mar 23, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | (6) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | (23) | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | (2) | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | (1) | Mar 14, 2016 |
| FY2013 | Dec 31, 2013 | 0 | Mar 13, 2014 |
| FY2013 | Sep 30, 2013 | 0 | Mar 13, 2014 |
| FY2013 | Jun 30, 2013 | 0 | Mar 13, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 0 | Mar 23, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | (6) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | (23) | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | (2) | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | (1) | Mar 14, 2016 |
| FY2013 | Dec 31, 2013 | 0 | Mar 13, 2014 |
| FY2013 | Sep 30, 2013 | 0 | Mar 13, 2014 |
| FY2013 | Jun 30, 2013 | 0 | Mar 13, 2014 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 2.46M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | 2.45M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 2.42M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 2.70M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 2.73M | Mar 23, 2020 |
| FY2018 | Dec 31, 2017 | 2.73M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 2.68M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | 26.23M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | 26.14M | Mar 14, 2016 |
| FY2014 | Dec 31, 2013 | 22.66M | Mar 13, 2015 |